Actavis asks court to let it stop manufacturing older Alzheimer's treatment

Actavis ($ACT) has made its case to a federal appeals court that it should be able to stop making the original version of its Alzheimer's treatment Namenda IR, which is going off patent, and replace it with its once-daily version Namenda XR, Reuters reports. Actavis had made the decision last year to stop manufacturing it as a way to get patients to switch to the newer version. The New York Attorney General sued the company over the ploy, which it called monopolistic. A lawyer for Actavis told the court it will lose about $200 million in sales if it cannot discontinue the older drug. Actavis has been ordered to manufacture both while it sorts the matter out in court. Story | More

Suggested Articles

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

Boehringer Ingelheim is investing $50 million in an animal health plant in Puerto Rico, adding 105 jobs.

Teva will begin producing chemo drug vincristine in the U.S. but has resisted the idea that its withdrawal from the market led to a shortage.